Skip to main content

Advertisement

Fig. 1 | BMC Cancer

Fig. 1

From: Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells

Fig. 1

CPT inhibits mTOR pathway by an unlike-rapamycin way in cancer cells. a Serum-starved Rh30 cells respectively expressing rapamycin-resistant mTOR (mTORrr), mTOR-wt and ad-GFP, were pretreated with CPT (10 μmol/L) for 2 h, then stimulated with IGF-1 (10 ng/mL) for 1 h. The western blotting assay was used to check the following proteins expression: Flag, p-S6K1, 4E-BP1, Cycin D1, Rb and β-tubulin. b Molecular docking for CPT binding to mTOR

Back to article page